CDCA5 and breast cancer: Therefore, this study aims to assess the expression of CDCA5 in BC at the mRNA (METABRIC cohort) and protein levels (Nottingham BC cohort) to evaluate its association with clinicopathological parameters including LVI and BC patient outcome.